Abstract
A new cyclometallated iridium(III) complex with the 2,2'-biquinoline N-donor ligand has been synthesized and characterized. The interaction and affinity of the complex towards c-myc G-quadruplex and duplex DNA have been investigated using UV/Vis spectroscopy and gel mobility shift assay. These studies revealed that complex 1 binds to c-myc G-quadruplexes (Pu22 and Pu27) with high affinity but does not interact with duplex DNA either by intercalation or groove binding. The ability of 1 to stabilize c-myc G-quadruplex DNA in vitro has also been examined through a PCR stop assay and a cell-based luciferase reporter assay. Complex 1 displays promising cytotoxic activity against the HeLa cell line with sub-micromolar potency.
Keywords: c-myc, DNA, G-quadruplex, iridium(III), metal complex, oncogene, promoter, cyclometallated iridium(III) complex, 2, 2'-biquinoline N-donor, G-quadruplex
Current Medicinal Chemistry
Title:A Cyclometallated Iridium(III) Complex As a c-myc G-Quadruplex Stabilizer and Down-Regulator of c-myc Oncogene Expression
Volume: 20 Issue: 4
Author(s): H. Yang, V. P.-Y. Ma, D. S.-H. Chan, H.-Z. He, C.-H. Leung and D.-L. Ma
Affiliation:
Keywords: c-myc, DNA, G-quadruplex, iridium(III), metal complex, oncogene, promoter, cyclometallated iridium(III) complex, 2, 2'-biquinoline N-donor, G-quadruplex
Abstract: A new cyclometallated iridium(III) complex with the 2,2'-biquinoline N-donor ligand has been synthesized and characterized. The interaction and affinity of the complex towards c-myc G-quadruplex and duplex DNA have been investigated using UV/Vis spectroscopy and gel mobility shift assay. These studies revealed that complex 1 binds to c-myc G-quadruplexes (Pu22 and Pu27) with high affinity but does not interact with duplex DNA either by intercalation or groove binding. The ability of 1 to stabilize c-myc G-quadruplex DNA in vitro has also been examined through a PCR stop assay and a cell-based luciferase reporter assay. Complex 1 displays promising cytotoxic activity against the HeLa cell line with sub-micromolar potency.
Export Options
About this article
Cite this article as:
Yang H., P.-Y. Ma V., S.-H. Chan D., He H.-Z., Leung C.-H. and Ma D.-L., A Cyclometallated Iridium(III) Complex As a c-myc G-Quadruplex Stabilizer and Down-Regulator of c-myc Oncogene Expression, Current Medicinal Chemistry 2013; 20 (4) . https://dx.doi.org/10.2174/0929867311320040009
DOI https://dx.doi.org/10.2174/0929867311320040009 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Female Infertility and Assisted Reproduction: Impact of Oxidative Stress-- An Update
Current Women`s Health Reviews Type 2 Diabetes, Insulin Secretion and β-Cell Mass
Current Molecular Medicine Patent Selections:
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Pharmacogenetic Determinants of Immediate and Delayed Reactions of Drug Hypersensitivity
Current Pharmaceutical Design Editorial: [Hot Topic: Central Nervous System Drugs in the Treatment of Neurological Disorders]
Central Nervous System Agents in Medicinal Chemistry Vitamin D Analogs as Modulators of Vitamin D Receptor Action
Current Topics in Medicinal Chemistry Macrophage Dysfunctions in Cystic Fibrosis Pulmonary Disease: Implications in Inflammation and Chronic Infections
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Statins and Alkylphospholipids as New Anticancer Agents Targeting Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry Effect of Recombinant Human Thymosin-α1, an Immuno-Modulating Peptide with 28 Amino Acids, on the Activity of Cytochrome P450s
Drug Metabolism Letters Recent Advances in Protein and Peptide Drug Delivery Systems
Current Drug Delivery Altering the Sphingosine-1-Phosphate/Ceramide Balance: A Promising Approach for Tumor Therapy
Current Pharmaceutical Design Short Peptide Modules for Enhancing Intestinal Barrier Function
Current Pharmaceutical Design Treatment of High-Grade Pelvic-Type Serous Carcinomas (Ovary, Fallopian Tube and Peritoneum): Current Therapeutic Paradigms, Prospects, and Challenges
Current Cancer Therapy Reviews Crosstalk between Inflammation and Coagulation: The Lessons of Sepsis
Current Vascular Pharmacology Identification of Functional Peptides from Natural and Synthetic Products on Their Anticancer Activities by Tumor Targeting
Current Medicinal Chemistry Prophylactic Activity of Biogenic Selenium Nanoparticles Against Chronic <i>Toxoplasma gondii</i> Infection
Recent Patents on Anti-Infective Drug Discovery Studies on the Pathophysiology and Genetic Basis of Migraine
Current Genomics How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design Acute Otitis Media in Children
Recent Patents on Inflammation & Allergy Drug Discovery Immunomodulatory Drugs (IMiDs) in Multiple Myeloma
Current Cancer Drug Targets